Psoriatic arthritis patients who stay on 1 anti-TNFi drug fare better

04/26/2013 | Family Practice News

Patients with psoriatic arthritis who switched to a second anti-tumor necrosis factor inhibitor drug had lower drug-survival rates at three years compared with those who remained on their first medication, researchers in Norway found. Switchers also showed much poorer responses in factors such as Disease Activity Score-28 remission and American College of Rheumatology-50 response than non-switchers. The findings were published in the journal Annals of the Rheumatic Diseases.

View Full Article in:

Family Practice News

Published in Brief:

SmartBrief Job Listings for Education

Job Title Company Location
Consultant - Los Angeles, CA (Full-time)
Insight Education Group
Encino, CA
Senior Turnaround Consultant (Job ID: 8274)
American Institutes of Research
Chicago, IL
Principal
Visible Men Academy
Bradenton, FL
Director, Department of Defense Dependents Schools, Europe
Department of Defense Education Activity (DoDEA)
Sembach
Senior Researcher\/Technical Assistance Consultant (8264)
American Institutes for Research
Washington, DC